350 related articles for article (PubMed ID: 36230543)
1. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer.
Hirschl N; Leveque W; Granitto J; Sammarco V; Fontillas M; Penson RT
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473293
[TBL] [Abstract][Full Text] [Related]
3. Emerging treatment options for ovarian cancer: focus on rucaparib.
Mariappan L; Jiang XY; Jackson J; Drew Y
Int J Womens Health; 2017; 9():913-924. PubMed ID: 29290694
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.
Bouberhan S; Philp L; Hill S; Al-Alem LF; Rueda B
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32403357
[TBL] [Abstract][Full Text] [Related]
5. Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.
Voutsadakis IA
Cancer Manag Res; 2020; 12():10423-10437. PubMed ID: 33116896
[TBL] [Abstract][Full Text] [Related]
6. Development of new medical treatment for epithelial ovarian cancer recurrence.
Mancari R; Cutillo G; Bruno V; Vincenzoni C; Mancini E; Baiocco E; Bruni S; Vocaturo G; Chiofalo B; Vizza E
Gland Surg; 2020 Aug; 9(4):1149-1163. PubMed ID: 32953630
[TBL] [Abstract][Full Text] [Related]
7. New perspectives on targeted therapy in ovarian cancer.
Coward JI; Middleton K; Murphy F
Int J Womens Health; 2015; 7():189-203. PubMed ID: 25678824
[TBL] [Abstract][Full Text] [Related]
8. Interplay between altered metabolism and DNA damage and repair in ovarian cancer.
Uboveja A; Aird KM
Bioessays; 2024 Jun; ():e2300166. PubMed ID: 38873912
[TBL] [Abstract][Full Text] [Related]
9. CXCL13 shapes tumor immune microenvironment in ovarian cancer with homologous recombination deficiency.
Ding Y; Ye Z; Ding B; Feng S; Du F; Ma X; Wang X; Shen Y
Genes Dis; 2024 Sep; 11(5):101200. PubMed ID: 38868578
[No Abstract] [Full Text] [Related]
10. Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Fleury H; Malaquin N; Tu V; Gilbert S; Martinez A; Olivier MA; Sauriol SA; Communal L; Leclerc-Desaulniers K; Carmona E; Provencher D; Mes-Masson AM; Rodier F
Nat Commun; 2024 May; 15(1):4011. PubMed ID: 38740764
[No Abstract] [Full Text] [Related]
11. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches.
Dilmac S; Ozpolat B
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509303
[TBL] [Abstract][Full Text] [Related]
12. A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt SJ; Shao N; Zatreanu D; Frankum J; Bajrami I; Brough R; Krastev DB; Roumeliotis TI; Choudhary JS; Lorenz S; Rust A; de Bono JS; Yap TA; Tutt ANJ; Lord CJ
Oncogene; 2023 Sep; 42(36):2701-2709. PubMed ID: 37491606
[TBL] [Abstract][Full Text] [Related]
13. Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers.
Parisi A; Rossi F; De Filippis C; Paoloni F; Felicetti C; Mammarella A; Pecci F; Lupi A; Berardi R
Onco Targets Ther; 2023; 16():585-613. PubMed ID: 37485307
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
15. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.
Willing EM; Vollbrecht C; Vössing C; Weist P; Schallenberg S; Herbst JM; Schatz S; Jóri B; Bataillon G; Harter P; Salutari V; Martin AG; Vergote I; Colombo N; Roeper J; Berg T; Berger R; Kah B; Noettrup TJ; Falk M; Arndt K; Polten A; Ray-Coquard I; Selzam F; Pirngruber J; Schmidt S; Hummel M; Tiemann M; Horst D; Sehouli J; Pujade-Lauraine E; Tiemann K; Braicu EI; Heukamp LC
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444554
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors in Breast and Ovarian Cancer.
Wang SSY; Jie YE; Cheng SW; Ling GL; Ming HVY
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190285
[TBL] [Abstract][Full Text] [Related]
17. Olaparib and advanced ovarian cancer: Summary of the past and looking into the future.
Maiorano BA; Maiorano MFP; Maiello E
Front Pharmacol; 2023; 14():1162665. PubMed ID: 37153769
[TBL] [Abstract][Full Text] [Related]
18. PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway.
Cao Q; Li L; Zhao Y; Wang C; Shi Y; Tao X; Cai C; Han XX
Cell Transplant; 2023; 32():9636897231187996. PubMed ID: 37488947
[TBL] [Abstract][Full Text] [Related]
19. Impact of DNA damage repair alterations on prostate cancer progression and metastasis.
Lukashchuk N; Barnicle A; Adelman CA; Armenia J; Kang J; Barrett JC; Harrington EA
Front Oncol; 2023; 13():1162644. PubMed ID: 37434977
[TBL] [Abstract][Full Text] [Related]
20. Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer.
Dong R; Ding T; Li Z
Front Pharmacol; 2023; 14():1164395. PubMed ID: 37426808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
